ARIAD Pharma (ARIA) Tops Q4 EPS by 2c

ARIAD Pharma (NASDAQ: ARIA) reported Q4 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $36.5 million versus the consensus estimate of $34 million.

Net product revenues from sales of Iclusig were $33.3 million for the fourth quarter of 2015, an increase of 56% from the fourth quarter of 2014.

• U.S. sales of Iclusig were $25.1 million for the fourth quarter, an increase of 48% from the fourth quarter of 2014.
• European sales of Iclusig were $8.2 million for the fourth quarter, an increase of 86% from the fourth quarter of 2014.

2016 Product Revenue Guidance

• Net product revenues from sales of Iclusig are expected to be in the range of $190 million to $200 million. This guidance includes sales of Iclusig in the U.S., Europe, and other select countries where ARIAD has distributorships in place.
• ARIAD will provide guidance on 2016 operating expenses at the time of completing its ongoing strategic review expected in the second quarter of 2016.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
• Oceanfirst Financial (OCFC) Reports In-Line Q2 EPS
• Contineum Therapeutics, Inc. (CTNM) Tops Q2 EPS by 4c